Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Callinan Royalties Corporation CCNMF

Metals & Mining Industrial Metals & Minerals


GREY:CCNMF - Post by User

Callinan Royalties Corporation
Bullboard Posts
User Avatar Image
(0)
•••
Comment by 13thon Feb 13, 2008 12:00am
218 Views
Post# 14363945

RE: Closing price

RE: Closing priceInNexus Biotechnology Inc. (OTCBB: IXSBF - News)(TSX VENTURE: IXS - News), (https://www.ixsbio.com) Chairman and CEO, Jeff Morhet will host a webcast teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss recent announcement with Royalty Pharma and preliminary results of an in vivo animal study exhibiting DXL625 (CD20)'s efficacy in reducing the growth rate of lymphoma cancer tumors. InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities